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Abstract 
Cushing’s disease (CD) is a rare cause of hypercortisolaemia caused by excessive 
adrenocorticotropic hormone (ACTH) excretion by a pituitary adenoma. Data on the 
predictive factors for the recurrence of the disease are limited in comparison with those for 
the adult population. The identification of the predictive factors for CD recurrence in patients 
after surgical treatment in childhood was the aim of the presented study. 
A retrospective analysis of 26 CD patients, mean age at the time of diagnosis 13.46 years, 
treated at the Children’s Memorial Health Institute (CMHI) in the years 1994–2018. Two 
time points were set at which the follow-up (FU) of patients was finished. The first time point 
(shorter FU, 24 patients) was set when the patients completed their treatment at the CMHI. 
The second time point (longer FU, 26 patients) was determined on the basis on the time when 
adult patients (previous CMHI patients) completed the author’s questionnaire. In the case of 
the other patients (current CMHI paediatric patients and patients who did not respond to the 
questionnaire), the latest FU in this second time point was made during the last visit to the 
CMHI. The predictors of disease recurrence were evaluated by the construction of a logistic 
regression model and receiver operating characteristics.  
The average FU after transsphenoidal pituitary surgery (TSS) of 26 patients was 10.23 years 
(0.67–24.50). Cushing’s disease recurrence occurred in four out of 26 patients (15.4%) after 
an average time of 3.6 years (0.92–8.08) following definitive treatment. The results of the 
statistical analysis of potential predictive factors for CD recurrence were not conclusive, with 
no variables confirmed above the statistical significance threshold of p < 0.05. As regards the 
longer FU, two potential predictors: mean cortisol level at night (p = 0.10) and max. 
adrenocorticotropic hormone level after ovine corticotropin-releasing hormone (oCRH) test 
(p = 0.10), were the closest to meeting the assumed threshold of statistical significance. 
Cushing’s disease recurrence may be diagnosed even a long time after its effective treatment.  
It is possible that cortisol levels at night and ACTH values in oCRH test before TSS may be 
helpful to predict which patients may experience a recurrence after successful initial 
treatment. However, further studies on a larger sample are needed to confirm this hypothesis. 
Key words: Cushing’s disease; recurrence; predictive factors; transsphenoidal pituitary 
surgery 
 
Introduction 
 Cushing’s disease (CD) is characterised by the excess production of 
adrenocorticotropic hormone (ACTH) by a pituitary corticotroph adenoma, which leads to 
hypercortisolaemia.  
The first-line treatment is pituitary transsphenoidal surgery (TSS) [1]. Remission rates in the 
paediatric population are reported to be 45-95% [2–7], and recurrence rates are 6–27% in 
children after an initial remission [Error! Bookmark not defined., Error! Bookmark not 
defined., 8]. Numerous researchers have attempted to determine the predictors for CD 
relapse. However, the results vary between studies, and currently no universal prognostic 
factor has been confirmed in all studies. Limited data indicate the potential prognostic factors 
of disease recurrence in children. Some predictive factors are common for both the paediatric 
and adult populations (such as: higher postoperative basal serum cortisol level and ovine 
corticotropin-releasing hormone [oCRH]-stimulated cortisol or ACTH levels, dural or 
petrosal sinus invasion, and no histopathological confirmation of pituitary corticotroph 
adenoma [9–12]), and others were reported only in children (e.g. older age at the onset of 
symptoms, younger age at the time of surgery, mutations in the USP8 gene in the resected 
tumour tissue [5, 6, 13]). In this study we present the results of the analysis of a group of 26 
patients after CD treatment in terms of the potential predictors for CD recurrence. 
 
Patients and methods  
Patient inclusion  
 Twenty-nine consecutive paediatric CD patients who had undergone endocrine 
evaluation and/or pituitary surgery at the Children’s Memorial Health Institute (CMHI) 
between 1993 and 2018 were initially included. The data of all patients had been previously 
reported [14]. The Institutional Bioethical Commission (48/KBE/2018) approved this study. 
Two patients with suspicion of recurrence and one patient with no follow-up (FU) after TSS 
were excluded, and for that reason the analysis of the predictive factors for CD recurrence 
was performed using the data of 26 patients in the long-term FU. Analysis based on the data 
only from CMHI patient medical records was performed in 24 patients because of no FU 
after TSS of two additional patients.  
 
Preoperative evaluation  
 The investigation and diagnosis of CD was performed as previously described [14]. 
Patients with negative preoperative magnetic resonance imaging or an incomplete endocrine 
evaluation underwent bilateral inferior petrosal sinus sampling to determine the source of 
ACTH secretion [15]. Cortisol levels at night were defined as the mean values of two 
respective measurements: cortisol level at 00:00 h and 00:30 h. The oCRH test was 
performed as follows: a venous catheter was inserted the night before the test. Ovine 
corticotropin-releasing hormone was administered at a dosage of 1 μg/kg (max. 100 μg) of 
body weight at 08:00 h. Samples for cortisol and ACTH were taken 5’ before administration 
and at 0’, 15’, 30’, and 45’ after the administration of oCRH [16, 17]. 
 
Histological analysis  
 Resected tumour tissues were analysed as previously described [14]. 
 
Latest follow-up 
 Two time points were set at which the FU of patients was finished. The first time 
point (shorter FU, 24 patients) was set when the patients completed their treatment at the 
CMHI. The second time point (longer FU) was determined on the basis of the time when the 
adult patient (previous CMHI patient) completed the author’s questionnaire. Answers to the 
questionnaire were obtained as previously described [14]. The patients were asked to indicate 
whether they had experienced a recurrence, whether they had a subsequent surgery, medical 
therapy, or pituitary radiotherapy, or were currently free of Cushing’s syndrome. They were 
asked to indicate whether they were currently taking any medications. In case of other 
patients (current CMHI paediatric patients and patients who did not respond to the 
questionnaire), the latest FU in this second time point was made during the last visit to the 
CMHI. The recurrence of CD was defined as the presence of the biochemical features of CD, 
i.e. increased midnight cortisol, the lack of suppression of cortisol during LDDST, and 
increased 24 h urinary free cortisol values, which recurred after successful treatment that 
resulted in clinical remission. Long-term remission was defined as previously described [14]. 
 
Statistical analysis 
 The paired-samples T-Test was used to determine significant differences when 
variables had normal distribution. The Mann-Whitney test was used to compare groups with 
non-normal variable distribution. Significance was assumed if p < 0.05. Predictors of disease 
recurrence were evaluated by the construction of a logistic regression model and receiver 
operating characteristics (ROC). Variables analysed in this model were: sex, age at the time 
of the disease onset, age at the time of surgery, Δ between age at surgery and the disease 
onset, mean morning serum cortisol level before treatment, serum cortisol at night, max. 
serum ACTH level before treatment, max. serum ACTH level after oCRH stimulation test 
(before TSS), time of hydrocortisone (HC) substitution (after TSS), adenoma visualisation in 
magnetic resonance imaging (MRI), dural/petrosal sinus invasion, and adenoma in 
histopathological examination. Data were analysed using Statistica 13 PL. 
 
Results 
 The mean time of observation of 24 patients  (10 females and 14 males) during care at 
CMHI (shorter FU) was 3.87 years (0.17–10.17) from TSS. Three patients (12.5%) recurred 
during this time at an average time of 4.50 yrs. (1.75–8.08) from definitive treatment. The 
mean time of longer FU of 26 patients (12 females and 14 males) was 10.41 yrs. (0.67–
24.50). Recurrence occurred in four of 26 patients (15.4%) at an average time 3.6 years 
(0.92–8.08) from definitive treatment. Three of these four recurred patients (75%) had 
hypocortisolism after TSS, and one (25%) patient had hypocortisolism after radiotherapy, 
which was used because biochemical remission after the second TSS was not achieved. 
Detailed characteristics of patients with recurrence were presented in the previous article 
[14]. 
Key characteristics of the variables used in the logistic regression for patients with and 
without CD recurrence are presented in Table 1. There was no significant difference between 
the patients with recurrence and the patients with long-term remission, regarding: height SDS 
and BMI SDS at presentation, age at the time of the disease onset, Δ between age at surgery 
and the disease onset, mean morning serum cortisol level before treatment, max. serum 
ACTH level before treatment, max. serum ACTH level after oCRH stimulation test (before 
TSS), time of HC substitution, height SDS, and BMI SDS at follow-up (Tab. 1). There were 
significant differences in age at the time of surgery (p = 0.55) and mean serum cortisol at 
night (p = 0.10). 
 Adenoma was visualised in MRI in 17/26 patients (65.4%). Two of the 26 patients 
(7.7%) presented with evidence of cavernous sinus invasion. None of these patients recurred. 
Histopathological examination confirmed a corticotroph adenoma in 20/26 (76.9%) patients. 
In two patients there were focal corticotroph hyperplasia and normal pituitary gland 
presented, respectively. Both patients were in remission at latest FU. In the remaining four 
patients there are no data on the result of histopathological examination (no data in patient 
medical records). 
 
Predictive factors for disease recurrence 
The median time of non-recurrence in the analysis with longer FU was 9.5 years (95% 
CI: 6.75–16.17) and 3.42 years (95% CI: 2.33–7.33) in the analysis with shorter FU (Fig. 1A 
and 1B). 
The results of analysis of predictive factors for CD recurrence in two groups — with shorter 
and longer FU – are presented in Table 2 and 3. It was checked whether there are variables 
differentiating patients with recurrence from patients without recurrence with sufficient 
statistical significance. No variables were confirmed above the statistical significance 
threshold of p < 0.05. As regards the longer FU, two factors: mean cortisol level at night and 
max. ACTH level after oCRH test, were closest to meeting the assumed threshold of 
statistical significance (Tab. 2 and 3). In the analysis, the increase of mean cortisol level at 
night increased the likelihood of recurrence, and the increase of max. ACTH level after 
stimulation in the oCRH test reduced the likelihood of recurrence. Adding interactions 
between variables (e.g. interaction: surgery age*max. ACTH, MRI result*time of HC 
substitution) did not make the logistic regression model significant at the level of statistical 
significance p < 0.05. A larger number of patients would be required to test the parameters 
mentioned above at this level of statistical significance. 
A unit increase of mean serum cortisol at night in odds ratio analysis increases the chance of 
recurrence by 16.3%. A unit increase of the value of max. serum ACTH after oCRH test 
reduces the chance of recurrence by 1.2% (p = 0.10) (Tab. 3). 
In addition, ROC analysis was performed in both groups for the mean cortisol concentration 
at night and max. ACTH after oCRH test, and cut-off points for these variables were found. 
A significant threshold value (p < 0.001) of mean serum cortisol at night was found and the 
best cut-off value for differentiating between remission and relapse was 17.5 µg/dL 
(sensitivity 70%, specificity 100%), and the receiver operating characteristic plot area under 
the curve (AUC) was 0.81. We found that an ACTH level of less than 98 pg/mL was the best 
cut-off value for differentiating between remission and relapse (sensitivity 63.2%, specificity 
100%, p = 0.07, AUC = 0.70).  
 
Discussion 
Numerous researchers attempted to find the predictive factors of CD recurrence. 
However, the results are not conclusive and, currently, no universal predictive factor has been 
confirmed in all studies. The predictive factors reported in the literature regarding both the 
paediatric and adult populations are: younger age at the time of TSS, larger tumour diameter, 
no identification of adenoma in MRI/intraoperatively, dural/petrosal sinus invasion, early 
postoperative recovery of normal function of the hypothalamic-pituitary-adrenal axis, no 
histopathological confirmation of pituitary corticotroph adenoma, and, following recent 
publications, mutations in the USP8 gene in the resected tumour tissue [Error! Bookmark 
not defined., Error! Bookmark not defined., Error! Bookmark not defined., 12, 18, 19].  
 In the presented study p was close to 0.05 for the following variables: the average 
cortisol level at night and max. ACTH level after oCRH test. This potentially signals a 
difference between the groups that, to be confirmed, requires further studies based on a 
larger sample. In the present study the increase of max. ACTH after oCRH reduced the 
likelihood of a recurrence (logistic regression ratio of –0.0123). In contrast, Lindsay et al. 
conducted a study in 332 patients (children and adults), which revealed that a higher level of 
ACTH values in oCRH test was a predictive factor for CD relapse [20]. In this study ACTH 
level was significantly lower in patients in a long-term remission compared to those who later 
experienced a recurrence (p < 0.007–0.02) [20]. 
A significantly elevated preoperative serum cortisol level was reported to be a 
predictive factor of CD recurrence in adults [21], while no study has confirmed this factor in 
children. Further studies should be conducted on larger samples to verify whether higher 
mean cortisol level at night could increase the possibility of recurrence after TSS. 
In contrast to a study carried out by Devoe et al. [Error! Bookmark not defined.], a 
positive correlation between younger age at the time of surgery and the recurrence was shown 
in our study (p = 0.55).  
Moreover, our study did not confirm the previous results concerning CD predictive 
factors regarding the paediatric population [6, 8, 18]. Lonser et al. demonstrated that dural 
invasion or petrosal sinus invasion and no intraoperative identification of adenoma may 
constitute the prognostic factors of CD recurrence [6]. Lodish et al. [18] reported that an early 
recovery of hypothalamic-pituitary-adrenal axis after TSS may indicate a disease recurrence 
(in our study the time of HC substitution was a tested factor). Batista et al. associated the 
following factors with a relapse: the lack of histological confirmation of an adenoma, higher 
ACTH and cortisol responses to oCRH (oCRH test after TSS), and glucocorticoid 
replacement for less than six months postoperatively [8].  
A limitation of our study is related to the fact that in many patients the recurrence status was 
not assessed biochemically at longer FU (in 75% of adult patients the data came from the 
questionnaire). Conversely, the extended FU is a major advantage of our study. The mean FU 
was 10.41 years, which is much longer than in other studies on the predictors of CD 
recurrence in children, e.g. Lonser et al. – 200 children with CD, mean postoperative follow-
up 6.8 ± 4.7 yrs., range 0.3–21.3 [Error! Bookmark not defined.]; Devoe et al. – 42 
children, mean follow-up 7.2 yrs., range 1.5–13.6 [Error! Bookmark not defined.]; Lodish 
et al. – 57 children, follow-up 6–36 months [18]; and Batista et al. – 72 children, follow-up 
24–120 months [Error! Bookmark not defined.]. Furthermore, the recurrence status could 
be confirmed on the basis of the questions in the questionnaire because they were very 
detailed. Moreover, a larger number of patients would be required to test the parameters 
mentioned above at the level of statistical significance of p < 0.05. Therefore, analysis with a 
shorter FU but based on the medical data from patient medical records with the biochemical 
assessment of the recurrence status was made. The average FU in this analysis is comparable 
with other studies conducted in the paediatric population. However, no prognostic factor was 
found in the group with shorter FU with the assumed statistical significance. 
 
Conclusions 
 Cushing’s disease recurrence may be diagnosed even a long time after effective 
treatment. It is possible that cortisol level at night and ACTH values in oCRH test before TSS 
may be helpful to predict which patients may experience a recurrence after successful initial 
treatment. However, further studies on a larger sample are needed to confirm this hypothesis. 
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Table 1. The characteristics of patients with Cushing’s disease (CD) recurrence (18% of 
patients) and patients with no recurrence (82% of patients) 
 Group A — patients with CD 
recurrence 
Group B — patients with no CD 
recurrence 
t-
studen
t test 
Mann-
Whitn
ey test 
 Count Mean Median Min Max SD Count Mean Median Min Max SD p U 
Height 
SDS at 
4 –
1.41 
–1.32 
–
2.47 
–0.54 0.89 22 –1.82 –1.54 
–
4.04 
–0.23 1.16 NS  
presentati
on 
BMI SDS 
at 
presentati
on 
4 
1.92 1.89 1.51 2.39 0.37 22 1.24 1.34 
–
1.61 
3.16 1.24 NS  
Age at the 
time of 
the 
disease 
onset [yrs] 
4 
9.55 10.10 5.50 12.50 3.06 22 9.96 10.78 4.33 16.00 2.69 NS  
Age at the 
time of 
surgery 
[yrs] 
4 
12.5
0 
12.04 9.08 16.83 3.22 22 13.53 14.42 5.42 17.25 3.15 
NS 
(P=0.5
5) 
 
Δ between 
age at 
surgery 
and the 
disease 
onset [yrs] 
4 
2.95 3.17 1.13 4.33 1.37 22 3.57 3.21 0.82 9.08 2.44 NS  
Mean 
morning 
serum 
cortisol 
level 
before 
treatment 
[µg/dL] 
4 
30.4
7 
26.58 
22.6
5 
46.08 
10.8
6 
22 28.30 24.03 
11.7
0 
79.82 15.63 NS  
Mean 
serum 
cortisol at 
night 
[µg/dL] 
4 
28.7
0 
23.88 
17.5
0 
49.53 
15.0
4 
20 18.31 14.15 8.20 51.70 10.30 
NS 
(P=0.1
0) 
 
Max. 
serum 
ACTH 
level 
before 
treatment 
[pg/mL] 
4 
96.5
0 
91.00 
68.0
0 
136.0
0 
28.4
9 
22 
116.1
2 
79.30 
16.0
0 
536.0
0 
106.5
3 
 NS 
Max. 
serum 
ACTH 
level after 
oCRH 
stimulatio
n test 
(before 
TSS) 
[pg/mL] 
3 
96.3
3 
95.00 
48.0
0 
146.0
0 
49.0
1 
18 
253.6
1 
143.50 
17.6
0 
1000.
00 
258.5
3 
 NS 
Time of 
HC 
substituti
on [yrs] 
4 
3.79 3.08 1.00 8.00 3.16 21 7.61 3.25 0.00 24.33 7.74 NS  
Height 
SDS at 
follow-up 
4 
-
0.96 
-0.58 
-
3.36 
0.68 1.71 22 -0.99 -1.09 
-
2.25 
1.01 0.85 NS  
BMI SDS 
at follow-
up 
4 
0.81 0.81 0.71 0.93 0.09 22 1.02 1.06 0.41 1.55 0.26 NS  
ACTH — adrenocorticotropic hormone; BMI — body mass index; oCRH — ovine corticotropin-
releasing hormone; TSS — transsphenoidal pituitary surgery; HC — hydrocortisone; NS — not 
significant 
 
Table 2. Results of the logistic regression model in groups with shorter and longer follow-up 
(FU) 
 
Logistic 
regression 
ratio 
Standard 
error 
Wald test 95% CI 
bottom 
95% CI top p 
Shorter FU 
Mean cortisol 
at night 
0.240 0.154 2.435 –0.061 0.542 p = 0.11 
Max. ACTH 
level after 
oCRH 
stimulation 
test (before 
TSS) 
–0.019 0.012 2.466 –0.043 0.05 p = 0.11 
Longer FU 
Mean cortisol 
at night 
0.1509 0.0994 2.31 –0.0439 0.3456 p = 0.10 
Max. ACTH 
level after 
oCRH 
stimulation 
test (before 
TSS) 
–0.0123 0.0080 2.37 –0.0279 0.0034 p = 0.10 
ACTH — adrenocorticotropic hormone; oCRH — ovine corticotropin-releasing hormone; TSS — 
transsphenoidal pituitary surgery; CI — confidence interval 
Table 3. Statistical analysis — odds ratio 
 Odds ratio (OR) 95% CI bottom 95% CI top p 
Shorter FU 
Mean cortisol at 
night 
1.271 0.940 1.719 0.11 
Max. ACTH level 
after oCRH 
stimulation test 
(before TSS) 
0.981 0.958 1.005 0.11 
Longer FU 
Mean cortisol at 
night 
1.163 0.957 1.413 0.10 
Max. ACTH level 
after oCRH 
stimulation test 
(before TSS) 
0.988 0.973 1.003 0.10 
ACTH — adrenocorticotropic hormone; oCRH — ovine corticotropin-releasing hormone; TSS — 
transsphenoidal pituitary surgery; CI — confidence interval 
 
 
Figure 1. Kaplan-Meier plot of recurrence-free survival in patients with remission of 
Cushing’s disease (CD) after transsphenoidal pituitary surgery (TSS); A. Follow-up (FU): 10.23 
years (0.67–24.50); B. FU: 3.87 years (0.17–10.17) 
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